{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:03:43Z","timestamp":1792533823830,"version":"4.5.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.jaci.2013.11.026","type":"journal-article","created":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T13:31:09Z","timestamp":1389360669000},"page":"921-923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":170,"title":["Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A\u00a012-month follow-up analysis"],"prefix":"10.1016","volume":"133","author":[{"given":"Pranabashis","family":"Haldar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.","family":"Brightling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amisha","family":"Singapuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Hargadon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bradding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth H.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Wardlaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2013.11.026_bib1","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.jaci.2013.11.026_bib2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2013.11.026_bib3","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2004.08.027","article-title":"Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700","volume":"114","author":"Kim","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2013.11.026_bib4","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jaci.2008.02.033","article-title":"Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex\u00a0vivo and increases IL-5 and IL-5 receptor levels","volume":"121","author":"Stein","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2013.11.026_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/ajrccm.161.1.9809100","article-title":"Changes in sputum eosinophils predict loss of asthma control","volume":"161","author":"Jatakanon","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2013.11.026_bib6","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jaci.2004.12.1129","article-title":"Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids","volume":"115","author":"Deykin","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2013.11.026_bib7","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1164\/ajrccm.163.2.9912091","article-title":"Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids","volume":"163","author":"Leuppi","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2013.11.026_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1183\/09031936.99.13101599","article-title":"Prednisone-dependent asthma: inflammatory indices in induced sputum","volume":"13","author":"Pizzichini","year":"1999","journal-title":"Eur Respir J"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674913018459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674913018459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:47:35Z","timestamp":1758790055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674913018459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0091674913018459"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2013.11.026","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A\u00a012-month follow-up analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2013.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}